Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Women in pharma

PME talks to Kay Wesley, CEO of Kanga Health, about her career in pharma

- PMLiVE

GSK’s antibiotic Blujepa granted FDA approval to treat urinary tract infections

Blujepa is the first in a new class of oral antibiotics for uncomplicated UTIs in nearly 30 years

- PMLiVE

J&J shares overall survival results for Rybrevant/Lazcluze combination in lung cancer

The regimen was approved by the MHRA earlier this month to treat EGFR-mutated NSCLC

- PMLiVE

FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome

The rare genetic disorder affects an estimated one in every 15,000 newborns in the US

- PMLiVE

Fox&Cat appoints Kim Walker as partner and managing director

Walker most recently served as managing director of GCI Health London

- PMLiVE

Innovation’s one real law

Playing with the NIH risks unintended consequences

- PMLiVE

The Cat’s Out of the Bag… Kim Walker, ex-GCI Health, Joins Fox&Cat as Partner and Managing Director

Fox&Cat appoints Kim Walker as Partner and Managing Director, bringing leadership strength and operational focus to the agency. Her arrival enhances Fox&Cat’s ADAPT™ methodology and consultancy model, reinforcing its commitment...

Fox&Cat

- PMLiVE

Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

Cardiovascular diseases result in an estimated 17.9 million global deaths each year

- PMLiVE

Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

Approximately 2.9 million people worldwide are living with the neurodegenerative disease

- PMLiVE

UKHSA releases list of pathogens posing ‘greatest risk’ to public health

The agency has listed 24 pathogen families where preparedness efforts are most needed

- PMLiVE

Mastering KAM excellence: achieving meaningful growth from top accounts

By Aaron Bean

- PMLiVE

Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links